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Original ArticleRfx6 promotes the differentiation of
peptide-secreting enteroendocrine cells
while repressing genetic programs
controlling serotonin productionJulie Piccand 1,2,3,4,6, Constance Vagne 1,2,3,4,6, Florence Blot 1,2,3,4,6, Aline Meunier 1,2,3,4,
Anthony Beucher 1,2,3,4, Perrine Strasser 1,2,3,4, Mari L. Lund 5, Sabitri Ghimire 1,2,3,4, Laure Nivlet 1,2,3,4,
Céline Lapp 1,2,3,4, Natalia Petersen 5, Maja S. Engelstoft 5, Christelle Thibault-Carpentier 1,2,3,4,
Céline Keime 1,2,3,4, Sara Jimenez Correa 1,2,3,4, Valérie Schreiber 1,2,3,4, Nacho Molina 1,2,3,4,
Thue W. Schwartz 5, Adèle De Arcangelis 1,2,3,4,**, Gérard Gradwohl 1,2,3,4,*ABSTRACT
Objective: Enteroendocrine cells (EECs) of the gastro-intestinal tract sense gut luminal factors and release peptide hormones or serotonin (5-HT)
to coordinate energy uptake and storage. Our goal is to decipher the gene regulatory networks controlling EECs speciﬁcation from enter-
oendocrine progenitors. In this context, we studied the role of the transcription factor Rfx6 which had been identiﬁed as the cause of Mitchelle
Riley syndrome, characterized by neonatal diabetes and congenital malabsorptive diarrhea. We previously reported that Rfx6 was essential for
pancreatic beta cell development and function; however, the role of Rfx6 in EECs differentiation remained to be elucidated.
Methods: We examined the molecular, cellular, and metabolic consequences of constitutive and conditional deletion of Rfx6 in the embryonic
and adult mouse intestine. We performed single cell and bulk RNA-Seq to characterize EECs diversity and identify Rfx6-regulated genes.
Results: Rfx6 is expressed in the gut endoderm; later, it is turned on in, and restricted to, enteroendocrine progenitors and persists in hormone-
positive EECs. In the embryonic intestine, the constitutive lack of Rfx6 leads to gastric heterotopia, suggesting a role in the maintenance of
intestinal identity. In the absence of intestinal Rfx6, EECs differentiation is severely impaired both in the embryo and adult. However, the number of
serotonin-producing enterochromafﬁn cells and mucosal 5-HT content are increased. Concomitantly, Neurog3-positive enteroendocrine pro-
genitors accumulate. Combined analysis of single-cell and bulk RNA-Seq data revealed that enteroendocrine progenitors differentiate in two main
cell trajectories, the enterochromafﬁn (EC) cells and the Peptidergic Enteroendocrine (PE) cells, the differentiation programs of which are
differentially regulated by Rfx6. Rfx6 operates upstream of Arx, Pax6 and Isl1 to trigger the differentiation of peptidergic EECs such as GIP-, GLP-
1-, or CCK-secreting cells. On the contrary, Rfx6 represses Lmx1a and Tph1, two genes essential for serotonin biosynthesis. Finally, we identiﬁed
transcriptional changes uncovering adaptive responses to the prolonged lack of enteroendocrine hormones and leading to malabsorption and
lower food efﬁciency ratio in Rfx6-deﬁcient mouse intestine.
Conclusion: These studies identify Rfx6 as an essential transcriptional regulator of EECs speciﬁcation and shed light on the molecular
mechanisms of intestinal failures in human RFX6-deﬁciencies such as MitchelleRiley syndrome.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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syndrome1. INTRODUCTION
Enteroendocrine cells (EECs) are one of the ﬁve main intestinal cell
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components) that trigger the secretion of peptide hormones or amines,
regulating food intake, digestion, or glucose metabolism. Peptide
hormones include Glucagon-Like Peptide 1 and 2 (GLP-1, GLP-2),
Peptide YY (PYY), Gastric Inhibitory Peptide (GIP), Somatostatin (SST),
Cholecystokinin (CCK), Secretin (SCT), Gastrin (GAST), Neurotensin
(NTS), and Ghrelin (GHRL). The monoamine serotonin (5-
hydroxytryptamine; 5-HT) is produced by enterochromafﬁn cells, the
most abundant enteroendocrine cell type. Historically, EECs were
classiﬁed using a one letter code based on their location and main
secretory product. However, co-expression [1,2] and single-cell tran-
scriptomic studies [3e6] tend to support the obsolescence of this
classiﬁcation [7] given that virtually all EECs express several hormones
albeit not at the same level. Recent ﬁndings suggest that the hormonal
repertoire of EECs might be modulated, along the cryptevillus axis, by
local signals [8]. Despite these major breakthroughs, our under-
standing of the molecular mechanisms controlling the differentiation of
EECs, both during development and renewal in the adult intestine, is
still limited.
Several transcription factors have been demonstrated to regulate EECs
differentiation. A master regulator is the basic helix-loop-helix (bHLH)
transcription factor Neurogenin3 (Ngn3 or Neurog3), which is
expressed in endocrine progenitors and determines endocrine
commitment in the embryonic [9e11] and adult intestine [12]. Neu-
rog3-expressing cells are rare hormoneenegative endocrine pro-
genitors conﬁned to the crypts and Neurog3 expression is turned off
when cells migrate towards the villi and differentiate into hormone-
expressing cells. Indeed, Neurog3-deﬁcient mice (constitutive and
intestinal deletion) lack EECs. The loss of all enteroendocrine cells in
mice leads to growth retardation, impaired lipid absorption, and
increased lethality, underlying the importance of enteroendocrine
function [12]. Neurog3-positive endocrine progenitors arise from in-
termediate crypt progenitors which express the bHLH transcription
factor Atoh1 [13]. Downstream of Neurog3, a complex network of
transcription factors controls the differentiation of subpopulations of
EECs such as NeuroD1 [14], Arx [15,16], Pax4 [15,17], Isl1 [18], Pax6
[17], Foxa1/2 [19], or Insm1 [20].
In almost all cases, transcription factors controlling EECs differentiation
also regulate pancreatic islet cell differentiation, suggesting shared
genetic programs. We and others have reported the critical role of the
transcription factor Regulatory Factor X 6 (Rfx6) in beta-cell develop-
ment [21,22] and function [23]. Rfx6, initially expressed broadly in the
gut endoderm, becomes restricted to the endocrine lineage in the
pancreas during embryogenesis and persists in adult islet cells. Rfx6 is
necessary for proper islet cell development in zebraﬁsh, mouse and
Xenopus [21,22,24]. Rfx6-deﬁcient mice lack alpha-, beta-, and delta-
cells, are diabetic, and die shortly after birth. Rfx6 loss in adult beta cells
leads to glucose intolerance, impaired beta-cell glucose sensing, and
defective insulin secretion [23]. A previous study reported the expres-
sion of Rfx6 in GIP-positive enteroendocrine K-cells and the regulation of
Gip promoter activity by Rfx6 [25]. Another recent study revealed that
loss of Rfx6 function ex vivo, in mouse intestinal organoids, led to a
reduction of EECs [5]. Still, detailed Rfx6 expression and role in mouse
intestine and EECs differentiation in vivo is unknown. In humans, several
mutations in RFX6 were identiﬁed as the cause of an autosomal
recessive syndrome, namedMitchelleRiley syndrome, characterized by
neonatal or childhood diabetes comprising hepatobiliary abnormalities
and intestinal atresia [22,26e33]. Most patients present with severe
congenital malabsorptive diarrhea, suggesting impaired EECs differ-
entiation; however, this has not been studied extensively.
In this study, we investigated the function of Rfx6 in EECs differen-
tiation in the embryonic and adult mouse. We show that EECsMOLECULAR METABOLISM 29 (2019) 24e39  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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only enterochromafﬁn cells are spared. Furthermore, we detected
patches of gastric cells in the small intestine of mutant newborns
indicating gastric heterotopia. Constitutive intestinal deletion of Rfx6
is found to be lethal at early post-natal stages. Deletion of Rfx6 in the
adult intestine is found to induce diarrhea, impaired lipid absorption,
and impaired food efﬁciency. Like in the embryo, adult EECs
expressing peptide hormones were either lost or decreased in rep-
resentation, while serotonin-positive enterochromafﬁn cells still
developed with even slight increase in their number. Concomitantly,
an increased number of Neurog3-positive enteroendocrine pro-
genitors was also observed. Contrary to in vivo data, the removal of
Rfx6 in small intestinal organoids was found to result in impaired
differentiation of all EECs, including enterochromafﬁn cells. By
comparative transcriptomic studies, we determined early Rfx6-
dependent targets in the EEC lineage and identiﬁed secondary
enhanced expression of neoglucogenic and nutrient absorption ma-
chinery genes reﬂecting adaptive response to the absence of
enteroendocrine hormones. In parallel single-cell transcriptomic
studies of EECs, we describe the dynamics of Rfx6 expression and
expression of other known and novel intestinal transcription factors.
Overall, our results show that enteroendocrine progenitors differen-
tiate in two main cell trajectories, the enterochromafﬁn (EC) cells and
the Peptidergic Enteroendocrine (PE) cells, the differentiation pro-
grams of which are differentially regulated by Rfx6.
2. MATERIAL AND METHODS
2.1. Animals and animal handling
All mice were housed in an animal facility licensed by the French
Ministry of Agriculture (Agreement no. B67-218-5), and all animal
experiments were supervised by GG (agreement no. C67-59) and
approved by the Direction des Services Vétérinaires in compliance
with the European legislation on care and use of laboratory animals.
Rfx6ﬂ/þ mice have been described previously [23] and were main-
tained on a C57BL/6N (Taconic) background. Rfx6þ/ mice have
been generated by crossing Rfx6ﬂ/þ females with CMV-Cre males.
Neurog3-Cre mice are a gift from Dr. Shosei Yoshida [34], and Villin-
Cre and Villin-CreERT2 were generously given by Dr. Sylvie Robine
[35]. Neurog3eYFP/þ mice have been described previously [36].
Studies in adult mice were performed with males unless otherwise
stated in ﬁgure legends. The proportions of mice from a given litter
were kept identical between control and mutant groups. Studies in
embryos were performed with combinations of males and females.
Genomic tail DNA was analyzed by PCR using the primers detailed
below. To achieve recombination in inducible mutants, adult mice
(8e12 weeks old) were treated with tamoxifen (10 mg) (Sigma) by
gavage twice per day, every second day during 5 days. Primers were
as follows:
Neurog3 Forward: ctgcagtttagcagaacttcagaggga
Cre Reverse: atcaacgttttgttttcgga
Villin forward: ataggaagccagtttcccttc
ERT forward: gcattaccggtcgatgcaacgagtgatgag
ERT reverse: aggatctctagccaggcaca
Rfx6 forward: gaaggtgcacccataaaagc
Rfx6 reverse: tataagccacccagggtcag
Neurog3 forward: cggcagatttgaatgagggc
Neurog3 reverse: tctcgcctcttctggctttc
GFP forward: cctgaagttcatctgcaccac
GFP reverse: ttgtagttgtactccagcttgtgccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 25
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Original Article2.2. Histopathology and immunohistochemistry
Mouse tissues were ﬁxed in 4% paraformaldehyde at 4 C overnight
and embedded in parafﬁn or Sandon Cryomatrix (Thermo Scientiﬁc).
Standard histology techniques were used: for conventional histology,
7 mm parafﬁn sections were stained with Harris hematoxylin and eosin
(H&E); for goblet cells analysis, 7 mm parafﬁn sections were stained
with Periodic Acid-Schiff (PAS) and hematoxylin or Alcian blue (AB) (pH
2.5); for lipid and fat deposits detection, 10 mm cryo-sections were
stained with Oil red O. Immunostaining on 7 (parafﬁn) or 10 (cryo) mm
sections was performed using standard protocols. For BrdU detection
assays, BrdU was injected intraperitoneally at 100 mg/kg body weight,
24 h prior sacriﬁce. If required, antigen retrieval was performed in
10 mM Sodium Citrate pH6 in a pressure cooker. Primary antibodies
used: guinea pig anti-Neurog3 1:1000 (M. Sander, UCSD, CA, USA);
goat anti-Neurog3 1:2000 (G. Gu, Vanderbilt University, TN, USA);
rabbit anti-Neurog3 1:500 (2763; IGBMC); rat anti-somatostatin 1:500
(Chemicon); mouse anti-ghrelin (C. Tomasetto, IGBMC, Illkirch,
France); goat anti-chromograninA 1:200 (Santa Cruz); goat anti-Cck
1:50 (Santa Cruz); guinea pig anti-glucagon 1:2000 (Linco); goat
anti-glp1 1:100 (Santa Cruz); goat anti-Gip 1:100 (Santa Cruz); goat
anti-gastrin 1:50 (Santa Cruz); goat anti-secretin 1:50 (Santa Cruz);
goat anti-serotonin 1:2000 (Abcam); rabbit anti-serotonin 1:2000
(Diasorin Incstar); rat anti-BrdU 1:10 (AbD Serotec), rabbit anti-Rfx6
1:500 (2766, IGBMC, Illkirch, France); chicken anti-GFP 1:2000
(Abcam). Secondary antibodies conjugated to Alexa Fluor 594,
DyLight 488, DyLight 549 and DyLight 649 (Jackson Immu-
noResearch) were used at 1:500. For BrdU, Neurog3, and Rfx6, signal
ampliﬁcation was performed using biotin anti-rabbit (Jackson Immu-
noResearch) coupled antibody at 1:500 and streptavidin-Cy3 (or-
Dylight 488) conjugate at 1:500 (Molecular Probes). Immunoﬂuores-
cent stainings on mouse intestinal organoids were performed as
previously described [37].
2.3. Generation and maintenance and 4-hydroxytamoxifen
treatment of mouse intestinal organoids
Mouse intestinal organoids were generated as previously described
[38] from small intestine of 2e6 month-old CD1 Neurog3eYFP/þ mice,
Rfx6ﬂ/ﬂ and Rfx6ﬂ/ﬂ; Villin CreERT2 mice. Brieﬂy, crypts from duodenum
or jejunum were isolated and cultured into Matrigel drops (Fisher
Scientiﬁc) to develop organoids in presence of the following me-
dium: Advanced DMEM/F-12, HEPES 10 mM, GlutaMax 2 mM, peni-
cillin/streptomycin 100 U/mL, supplement B27 1X (all from Gibco),
N-acetyl-L-cysteine 1 mM (Merck), human recombinant R-spondin-1
500 ng/mL (PeproTech), murine recombinant EGF 50 ng/mL
(PeproTech) and human recombinant Noggin 100 ng/mL (R&D
Systems). Organoids were maintained at 37 C, 5% CO2 and were
split into 24-well plates every 5e7 days. To induce in vitro Cre
recombinase activation and speciﬁc deletion of Rfx6, organoids derived
from Rfx6ﬂ/ﬂ (controls) and Rfx6ﬂ/ﬂ; Villin-CreERT2 duodenum (n ¼ 4
per genotype) were treated two days after seeding with 4-
hydroxytamoxifen (4-OHT; SigmaeAldrich) 1.25 mM for 15 h, after
which the medium was replaced with fresh medium without 4-OHT.
Organoids were harvested 8 days after 4-OHT treatment for RNA
extraction.
2.4. Measurement of intestinal serotonin content
Eleven days post tamoxifen treatment, four adult males Rfx6ﬂ/ﬂ and
three Rfx6ﬂ/ﬂ Villin-CreERT2 were euthanized by cervical dislocation
and the entire gastrointestinal tract was excised. Using dermal biopsy
punches (1.5 mm), intestinal samples were obtained from relevant
sites throughout the GI tract (duodenum, jejunum, ileum, proximal26 MOLECULAR METABOLISM 29 (2019) 24e39  2019 The Authors. Published by Elsevier GmbH. T
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puriﬁed in ice-cold 1 M perchloric acid to precipitate proteins.
Following centrifugation at 14.000G at 4C, 15 min, after which the
supernatant was collected and taken through an additional purifying
step adding a similar volume of 1 M perchloric acid followed by mixing
and centrifugation. The protein-free samples were diluted 2 or 10
times in MilliQ water prior HPLC injection (10 ml). 5-HT concentration
was measured by HPLC-ECD (HTEC-500, Eicom) with a PP-ODS2
column (Amuza) following manufacturer’s instructions regarding ﬂow
rate, mobile phase and applied potential. Retention time (3.8 s) for 5-
HT was determined by a control 5-HT dilution of 1pM (SigmaeAldrich).
Results are stated as area under the curve (AUC) and presented as
mean  SD. Unpaired T-test was applied to calculate signiﬁcance
(*p  0.05; **p  0.01).
2.5. Morphometric analysis
Neurog3-positive cells or Neurog3/BrdU double positive cells were
counted in adult mice after immunostaining on approximately 50
sections of duodenum, jejunum, ileum and colon three months after
tamoxifen treatment (n ¼ 3 per genotype). The number of Neurog3-
positive cells was normalized according to the area of the sections
estimated by the surface of DAPI staining. The number of Neurog3/
BrdU double positive cells was normalized to the total number of
Neurog3 cells, and expressed as a percentage. 5-HT positive cells
were counted after immunostaining on sections of duodenum and
ileum from adult animals (n ¼ 3 per genotype), one week after
tamoxifen treatment. At least 50 well-oriented crypt-villus sections per
animal were analyzed and as indicated above the number of 5-HT-
positive cells was normalized according to the DAPI-positive area.
2.6. Metabolic studies
Mice were fed with normal chow diet (DO3, SAFE) from weaning.
Glucose tolerance tests were performed as described previously [23].
Food intake and feces production were measured over a 48 h period.
Feces energy content, energy excretion, energy ingested and food ef-
ﬁciency were measured by the Mouse Clinical Institute (MCI) metabolic
platform (http://www.ics-mci.fr). Blood analyses were performed on
plasma from adult males by the MCI. The energy content of the stools
was evaluated using a bomb calorimeter (C503 control, IKA). The energy
excreted was calculated as feces energy content (Cal/g) X feces weight
(g)/2. The energy ingested was calculated as food intake per day (g) X
diet caloriﬁc value (3.5 kcal/g). The energy excreted was calculated by
the difference between total calories ingested and excreted in feces.
Food efﬁciency is the ratio of energy ingested/energy excreted per day.
2.7. Statistics
Comparisons of means and medians were performed with Graphpad
Prism 7.0 or R software. Values are presented as mean  SD or SEM.
p-values were determined using the 2-tailed Student t-test with un-
equal variance or the 2-tailed nonparametric test of ManneWhitney
offered in Prism. p  0.05 was accepted as statistically signiﬁcant.
2.8. Dissociation of mouse intestinal organoids into single cells
Organoids were dissociated to single cells as previously described,
with some modiﬁcations [3]. Brieﬂy, after medium removal and
Matrigel disruption, organoids were dissociated in 500 mL of TrypLE
Express Enzyme (1X) (Gibco) at 37 C for 20 min, assisted by a
mechanical dissociation (up and down with a p1000 and a ﬁnal pas-
sage through a syringe ﬁtted with a 18G needle). The dissociation was
stopped in a medium containing Advanced DMEM/F-12, fetal calf
serum 10%, N-acetylcysteine 0.5 mM, and supplement B27 1X. Thehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.comen from ClinicalKey.com by Elsevier on November 19, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
cells were pelleted, washed 2 times, and resuspended in the same
medium. Finally, they were strained through a 50 mm cell strainer, and
stained with DAPI (to exclude dead cells) before to be sorted by ﬂow
cytometry (FACSAria Fusion, BD).
2.9. RNA isolation and qPCR
Total RNA from whole small intestine (pups), duodenum (adults),
jejunum (adults), ileum (adults), or colon (pups and adults) was
extracted using TRI Reagent (Invitrogen) or RNeasy Midi Kit (Qiagen),
according to the manufacturer’s instructions. Total RNA from orga-
noids was extracted using RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. Reverse transcription was performed
using Transcriptor Reverse Transcriptase (Roche) and Random primers
(Roche). Quantitative PCRs were performed using mouse-speciﬁc
TaqMan primers and probes (Applied Biosystems) recognizing Neu-
rog3 (Mm00437606_s1), ChgA (Mm00514341_m1), Arx (Mm0054
5903_m1), Pax4 (Mm01159036_m1), Pax6 (Mm00443081_m1), Isl1
(Mm00517585_m1), Lmx1a (Mm00473947_m1), Tac1 (Mm0116
6996_m1), Ucn3 (Mm00453206_s1), NeuroD1 (Mm00520715_m1),
Pyy (Mm00520715_m1), Nts (Mm00481140_m1), Cck (Mm004461
70_m1), Sct (Mm00441235_g1), Gip (Mm00433601_m1), Gcg/Glp1
(Mm00801712_m1), Tph1 (Mm00493794_m1), Gast (Mm0077221
1_g1), Sst (Mm00436671_m1), Ghrl (Mm00445450_m1), Nkx2.2 (as
described in Gross S. et al., 2016; Forward primer: cctccccgagtgg-
cagat; Reverse primer: gagttctatcctctccaaaagttcaaa; FAM-MGB Probe:
ccattgactctgccccatcgctct) or UPL probe #83 for Rfx6 (Forward primer:
tgcaggaaagagaaactggag; Reverse primer: ggaaatttttggcgaattgtc), with
Light Cycler 480 Probes Master Mix (Roche) on Light Cycler 480
(Roche). Gene expression levels were normalized to Rplp0
(Mm01974474_gH).
2.10. Microarrays
Samples processing: Microarray analysis was performed according to
Agilent protocol “One-Color Microarray-Based Gene Expression Anal-
ysis e Low Input Quick Amp Labeling” version 6.5, May 2010 (Cat
#G4140-90040). Complementary RNA (cRNA) samples were linearly
ampliﬁed and labeled with cyanine 3 starting from 100 ng of total RNA.
Following fragmentation, labeled cRNA were hybridized on Agilent
“SurePrint G3 Mouse Gene Expression 8  60 K Microarray” (Design
ID: 028005), for 17 h, at 65 C under 10 rpm. Following washing, the
slides were scanned using an Agilent G2565CA microarray Scanner
System, at a 3 mm resolution in a 20-bit scan mode, according to the
“AgilentG3_GX_1Color” protocol. Data analysis: Raw.tif images were
then extracted using Agilent “Feature Extraction, version 10.10.1.1”
following “GE1_1010_Sep10” protocol. Median raw expression values
were further normalized by quantile method [39]. Differential expres-
sion analysis between Rfx6/ vs controls and Rfx6DEndo vs controls
were performed using the R package limma version 3.36.5 [40]. Data
have been deposited in GEO repository (GSE133038).
2.11. RNA sequencing
Ilea from adult Rfx6DAdInt mice was harvested at 8 days and 3 months
after tamoxifen gavage. Total RNA was extracted using TRI-reagent or
RNeasy Midi Kit (Qiagen). Libraries were prepared using the total
RNA-seq Ribo-zero protocol and sequenced on an Illumina HiSeq 2500
(single-end 50bp reads). Reads were identiﬁed and mapped onto the
mm9 assembly of mouse genome using Tophat version 2.0.10 and the
Bowtie2 version 2.1.0 aligner. Quantiﬁcation of gene expression was
performed using HTSeq version 0.6.1 and gene annotations from
Ensembl release 67. Normalization of read counts and differential
expression analysis between controls and Rfx6DAdInt samples wereMOLECULAR METABOLISM 29 (2019) 24e39  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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2.12. Single-cell RNA-Seq; sample processing
eYFPþ cells, from dissociated Neurog3eYFP/þ intestinal organoids, were
sorted directly into four 96 well plates « Precise WTA Single Cell
Encoding Plate » (BD Precise WTA Single Cell Kit, BD Genomics) (1
cell/well) using a FACSAria Fusion (BD). DAPI was used to sort only
living cells. The library was prepared according to manufacturer’s
recommendations (910000014 Rev. 02 11/2016, BD Genomics) and
sequenced on an Illumina HiSeq 4000 using paired-end 2  100bp
lanes sequencing. Data were deposited in GEO repository (GSE133038).
2.13. Single-cell RNA-Seq analysis
2.13.1. Demultiplexing, alignment and quantiﬁcation
Fastq ﬁles were demultiplexed using the sample index encoded in
reads 1. Reads 2 having a bad quality (–quality-cutoff 20,20) or cor-
responding to polyA sequences or to adapters were removed using
Cutadapt version 1.10. Reads 2 mapping to rRNA were identiﬁed using
Bowtie 2 version 2.2.8 and removed. Reads 2 were aligned to mm10
genome using STAR version 2.5.3a. After alignment, reads corre-
sponding to technical duplicates were removed using UMI-Tools
version 0.4.4 (method: “directional-adjacency”) [42]. Quantiﬁcation
of gene expression was performed using HTSeq version 0.6.1.post1
(parameter “–mode union”) and gene annotations from Ensembl
release 90.
2.13.2. Quality ﬁltering of cells
Cells were ﬁltered according to several quality criteria: (i) percentage of
reads uniquely aligned to genome had to be superior or equal to 40%,
(ii) percentage of UMIs assigned to genes had to be superior or equal to
50%, (iii) number of assigned UMIs had to be superior or equal to
200,000, (iv) proportion of UMIs assigned to mitochondrial genes had
to be inferior to 20%. Finally, 290 cells were kept for further analyses.
Among these ﬁltered cells, the number of assigned UMIs varies from
200,000 to 2.3 million. Regarding the number of expressed genes per
cell, it varies from 2,777 to 10,019 with a median equal to 4,606.
2.13.3. Normalization, dimensionality reduction, and clustering
Data were then analyzed using the Seurat package version 2.3.4 [43].
Before creating the Seurat object, a gene ﬁltering was performed. On
the 29,161 genes expressed in the data, only 9,057 were retained as
they met two criteria: they were coding genes or lincRNA and had at
least 5 UMIs assigned in 5 samples. The normalization and scaling of
the data were performed using the functions NormalizeData (method
“LogNormalize”) and ScaleData implemented in Seurat.
Variable genes were identiﬁed using the FindVariableGenes function in
the Seurat package: the 830 genes having a scaled dispersion superior
or equal to 1 and a log-normalized average expression superior or
equal to 0.2 were selected as variable genes. Then, a PCA (Principal
Component Analysis) was done with the function RunPCA of Seurat,
based on these 830 variable genes. The 13 ﬁrst axes were used to
create an UMAP, as they had a signiﬁcant PCA score, according to the
“Jack Straw” approach implemented in Seurat. The UMAP was per-
formed with the function RunUMAP in Seurat (n_neighbors ¼ 20 and
min_dist ¼ 0.3). Finally, the clustering was performed based on the
two ﬁrst axis of the UMAP, using the SNN (shared nearest neighbor)
modularity optimization algorithm implemented in the FindClusters
function of Seurat. The following parameters were used:cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 27
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of cells were found.
2.13.4. Identiﬁcation of markers of the groups
Before performing the differential expression analysis, genes were
ﬁltered. On the 9,057 already ﬁltered genes, we kept only 8,644 genes
as they had a normalized expression equal or superior to 1 in at least
1% of the cells. Differential expression analysis was done using the
QLF (quasi-likelihood) approach implemented in the R package edgeR
version 3.20.6 [44]. The detection rate was added as a covariate to the
model as it improves the performance of the analysis [45]. To compare
one group of cells to the others, we used the following contrasts: 1 for
said group and 1/7 for the seven other groups. One gene was
considered as the marker of a group if it was signiﬁcantly over-
expressed in this group with a FDR inferior or equal to 1010 and if
it was expressed in at least 20% of the cells of the said group.
2.13.5. Cell trajectory
The log-transformed gene expression matrix of the 830 variable genes
was used to generate diffusion map, using the function DiffusionMap
(k ¼ 15) implemented in destiny R package, version 2.12.0 [46].
3. RESULTS
3.1. Rfx6 is expressed in endocrine progenitors in the crypts and in
all nascent hormone-expressing cells at the base of villi in the adult
mouse intestine
To determine Rfx6 intestinal expression, we performed a series of
immunoﬂuorescence experiments in the embryo, as well as in adult
CD1 mice (Figure 1). It was previously shown that Rfx6 is expressed
broadly in the gut endoderm at E9 [21,22]. From E13.5, Rfx6Figure 1: Expression of Rfx6 in the intestinal endocrine lineage of embryonic and a
cryosections of embryonic E15.5 (A) and adult small intestine (BeC). Yellow arrows point to
and ChromograninA (ChgA), Glucagon like peptide-1 (GLP-1), Gastric Inhibitory Polypeptide
Gastrin (Gast), in green. Nuclei are stained with DAPI (blue). Scale bar 10 mM.
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bryonic intestine in a pattern of developing enteroendocrine cells
(Figure 1A and Suppl. Figure 1A-C). Accordingly, we found that Rfx6
is expressed in Neurog3-positive enteroendocrine progenitors during
embryogenesis and in the adult small intestine. Indeed, we observed
that Rfx6 is expressed in a subset of crypt based Neurog3-positive
endocrine progenitor cells (40%; n ¼ 300; Figure 1BeD). The ma-
jority of Rfx6-positive-nuclei are found in the crypts
(Suppl. Figure 1D-F). Nevertheless, Rfx6 is maintained in hormone-
expressing enteroendocrine cell types including incretin (GLP-1 and
GIP) producing cells, as well as 5-HT enterochromafﬁn cells
(Figure 1GeN, Suppl. Figure 1D,E). We observed that cells positive
for both Rfx6 and hormones show different intensities of Rfx6 staining
along the crypt-villus axis. Rfx6 staining appears to be strongest in
the crypts and in the lower part of villi and becomes weaker while
enteroendocrine cells differentiate and migrate up toward the villus
top (Figure 1J). Indeed, Chromogranin A (ChgA)-positive or 5-HT-
positive/Rfx6-negative cells can be found at the villus top indicating
gradual loss of Rfx6 as enteroendocrine cells differentiate and
migrate up (Figure 1F, Suppl. Figure 1D,E). In contrast, all GIP-
expressing cells expressed Rfx6 (Suppl. Figure 1F).
3.2. Ectopic expression of gastric genes and impaired
enteroendocrine cell differentiation in the embryonic intestine
lacking Rfx6
At ﬁrst, Rfx6 is expressed in the embryonic gut endoderm and then
becomes restricted to the enteroendocrine lineage at later stages of
development suggesting different roles. To decipher Rfx6 intestinal
functions, we compared the transcriptome of the embryonic small
intestine of Rfx6 null mice (Rfx6/) as well as of mice with an
endocrine speciﬁc deletion of the gene (Rfx6ﬂ/ﬂ; Neurog3-Cre; calleddult mice. (AeD) Double immunoﬂuorescence for Rfx6 (green) and Neurog3 (red) on
Rfx6/Neurog3 double positive cells. (EeN) Double immunoﬂuorescence for Rfx6 in red
(GIP), Somatostatin (SST), Serotonin (5-HT), Ghrelin (Ghrl), Cholecystokinin (CCK), and
his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Severe impairment of enteroendocrine cell differentiation in the gastro-intestinal tract of Rfx6-deﬁcient embryos and presence of gastric heterotopia in
mutant neonates. (A, B) Gene expression proﬁling of the embryonic small intestine of mice with constitutive (Rfx6/) or endocrine-speciﬁc deletion (Rfx6DEndo) of Rfx6 at E18.5.
(A) Rfx6 / vs control comparison (micro-array data). MA-plot representing the log Fold-Change as a function of the mean of normalized intensity. Green and red points represent
signiﬁcantly (Adjusted p-value  0.1) up- and down-regulated genes, respectively. (B) Rfx6DEndo vs control comparison (micro-array data). MA-plot representing the log Fold-
Change as a function of the mean of normalized intensity. Green and red points represent signiﬁcantly (Adjusted p-value  0.1) up- and down-regulated genes, respectively.
(C) RT-qPCR analysis of gastric genes in the small intestine of Rfx6/ and wild-type mice at E18.5. Analysis was performed on n ¼ 4 animals per genotype. (D) Immuno-
ﬂuorescence for TFF1 on small intestine cryosections of control and Rfx6/ new born mice revealing gastric heterotopia. (E) RT-qPCR analysis of relevant genes in the stomach
(P0.5) of Rfx6/ and wild-type mice. Analysis was performed on n ¼ 4 animals per genotype. Data are represented as mean  SD; unpaired t-test, ****p  0.0001 ***,
p  0.001, **p  0.01, *p  0.05, ns: not signiﬁcant. AU stands for Arbitrary Unit. SI: Small Intestine. E18.5: Embryonic day 18.5. P0.5: postnatal day 0.5.
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Original Articlethereafter Rfx6DEndo) to wild-type controls. We observed a strong
down-regulation of the vast majority of genes encoding enter-
oendocrine hormones, Gcg (stands herein for preproglucagon gene),
Gip, Ghrl, Sst, Nts, Cck, Pyy, Sct, both in Rfx6/ as well as in
Rfx6DEndo intestine (Figure 2A,B, Suppl.Tables 1 and 2). Lmx1a, a
transcription factor regulating Tph1 expression and thus important for
5-HT production in EC cells, is up-regulated in Rfx6/ intestine (Fold
Change (FC) ¼ 1.7; adjusted p-value ¼ 0.01). Indeed, recent studies
revealed the importance of Nkx2-2 transcription factor for entero-
chromafﬁn cell differentiation through control of Lmx1a expression
[47]. Lmx1a in turn transactivates Tph1 encoding Tryptophan hy-
droxylase 1, the rate-limiting enzyme for the production of peripheral
serotonin. Accordingly, we observed a trend for Tph1 to increase
(FC ¼ 1.3; p-value 0.016; adjusted p-value ¼ 0.13).
Unexpectedly, transcriptome comparison revealed that many gastric
genes were strongly up-regulated in Rfx6/ (Figure 2A), but not in
Rfx6DEndo embryonic intestine (Figure 2B), compared with wild-
type. These genes include Gkn2, Tff1, and Muc5b, which are
normally expressed in pit cells of the gastric glands, as well as
Atp4b, which encodes a subunit of the gastric proton pump
expressed in parietal cells of the fundic gland. These data suggest
that heterotopic gastric mucosa forms in the small intestine of Rfx6-
deﬁcient mice. We were able to conﬁrm this hypothesis by RT-qPCR
for Gkn2 and Tff1 and, at the protein level, for TFF1 (Figure 2C,D).
In agreement with the transcriptomic data, we found many patches
of TFF1-positive cells in the small intestine of Rfx6-deﬁcient
newborn mice but never in controls. Next, we investigated gastric
enteroendocrine cell differentiation. Tph1 expression was, similarly
to the intestine, up-regulated, while the expression of Gast, Sst, and
Ghrl was severely decreased in the stomach of Rfx6-deﬁcient
newborn mice (Figure 2E). Thus, our study suggests that, in the
mouse embryo, Rfx6 controls enteroendocrine cell differentiation in
the gastro-intestinal tract and is required for the maintenance of
intestinal cell identity.
3.3. Constitutive, but not adult-induced intestinal deletion of Rfx6,
is lethal
To further study Rfx6 intestinal function and to bypass any effect
related to its pancreatic function, we generated intestine-speciﬁc Rfx6-
deﬁcient mice (Rfx6ﬂ/ﬂ; Villin-Cre, referred as Rfx6DInt). Rfx6DInt mice
died shortly after birth (between P2eP5, n ¼ 14 litters), except one
animal who survived up to 13 weeks. The presence of milk in the
stomach testiﬁed that mutants were fed properly; however, they
sometimes failed to thrive. Similarly to Rfx6/ embryonic intestine,
RT-qPCRs revealed that Gcg, Gip, Cck, Pyy, Nts, Sst, and Ghrl tran-
scripts are mostly undetectable in newborns Rfx6DInt small intestine,
Sct is decreased and Tph1 increased (Suppl. Figure 2). Because of the
early lethality of Rfx6DInt pups, the role of Rfx6 in the adult intestine
could not be studied in this model. We thus generated mice with an
inducible deletion of Rfx6 (Rfx6ﬂ/ﬂ; Villin-CreERT2, referred as Rfx6DA-
dInt). Tamoxifen gavage efﬁciently deleted Rfx6, as shown by the
absence of wild-type Rfx6 mRNA and protein in the small intestine and
the colon of Rfx6DAdInt mice 8 days after treatment (Suppl. Figures 3
and 5A). Rfx6DAdInt mice started to lose weight one week after
tamoxifen treatment, however they caught up 7 days later (Figure 3A).
Only one Rfx6DAdInt mouse did not overcome the weight loss and died
11 days after the beginning of the treatment. Thus, except this single
case, we did not observe any death upon Rfx6 intestinal deletion in the
adult mouse (n  100). In summary, the lack of functional intestinal
Rfx6 is lethal at early postnatal stages but is not life threatening in the
adult mice.30 MOLECULAR METABOLISM 29 (2019) 24e39  2019 The Authors. Published by Elsevier GmbH. T
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impairs lipid absorption and food efﬁciency
We next investigated the metabolic consequences of induced intes-
tinal deletion of Rfx6 in the adult mice one month after tamoxifen
treatment. First, we noticed that mutant mice exhibited liquid and
yellowish stools (Suppl. Figure 4A,B), suggesting diarrhea and ste-
atorrhea. In agreement with the later hypothesis, Oil red O staining of
the mutant gut revealed a clear reduction in the presence of neutral
lipids content in the enterocytes and the lamina propria in the small
intestine as well as accumulation of lipid droplets in the colon
(Figure 3B). In addition, although total cholesterol and HDL levels are
not affected, levels of LDL cholesterol were reduced in the serum of
Rfx6DAdInt mice (Figure 3CeE). Triglycerides concentrations were
also reduced, but not signiﬁcantly (p ¼ 0.11), free fatty acids and
glycerol levels were not affected (Figure 3FeH). Since serum
pancreatic lipase levels are unchanged (Figure 3I), these results
suggest that the reduced numbers of Oil red O-positive lipid droplets
and the reduced serum levels of LDL cholesterol found in Rfx6DAdInt
mice are due to impaired lipid absorption rather than impaired lipid
processing.
Glucose clearance was explored by oral (OGTT) and intraperitoneal
(IPGTT) glucose tolerance tests (Figure 3N,O). After glucose gavage,
blood glucose concentration raised similarly in mutant and control
mice suggesting normal intestinal glucose absorption. OGTT
revealed that Rfx6DAdInt mice are slightly glucose intolerant. This
effect could result from the lack of incretin hormones. Indeed, when
the incretin effect is bypassed in IPGTT, glucose clearance is un-
changed. To further characterize these mice, we performed ana-
lyses of food efﬁciency (Figure 3JeM). Mice, in which Rfx6 was
deleted from the adult intestine, showed an increased production of
feces due, at least in part, to an increased food intake (Figure 3Je
K). Fecal energy measurement, using bomb calorimetry (Figure 3L),
revealed fecal energy loss in Rfx6DAdInt mice compared to the
controls, suggesting malabsorption. Despite increased food intake,
Rfx6DAdInt mice have a decreased food efﬁciency ratio (Figure 3M).
Of note, these metabolic studies were performed with adult males
and thus, results could eventually be different with females.
Together, these data suggest that decreased food efﬁciency of
Rfx6DAdInt mice could result from diarrhea and lipid malabsorption.
This is in agreement with previous work in mice lacking all
enteroendocrine cells [12] as well as with symptoms of Mitchelle
Riley patients [22].
3.5. Impaired production of all enteroendocrine hormones except
serotonin which is increased in Rfx6-deﬁcient adult intestine
To decipher the mechanisms underlying Rfx6 function in the adult
intestine, we determined the genes differentially expressed in the
ileum upon Rfx6 removal one week (Figure 4AeC, Suppl. table 3) and
3 months (Figure 4DeF, Suppl. table 4) after tamoxifen treatment by
RNA sequencing. RT-qPCR were also performed in other segments of
the small intestine and in the colon (Suppl. Figure 5). This strategy
allowed us to identify early targets and later transcriptome changes.
RNA-Seq revealed that 78 and 74 genes were found up and down-
regulated, respectively, 1 week after tamoxifen treatment (Adjusted
p-value  0.05) while these numbers increased to 1393 and 1483
after 3 months, suggesting adaptive responses. Overall, we found that
transcripts for many intestinal hormones are almost undetectable (Gcg,
Pyy, Gip, Ghrl, Nts) or decreased (Cck, Sst, Nts, Sct) in the small in-
testine of Rfx6DAdInt mice compared to controls (Figure 4B,E,
Suppl. Figure 5B). Gcg and Pyy transcripts are decreased as well in the
mutant colon (Suppl. Figure 5B). In sharp contrast, Tph1, encoding thehis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.comen from ClinicalKey.com by Elsevier on November 19, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
0
5
10
15
20
25
30
35
0 1 2 3 4 7 9 11 14 17 21 28 35 42 49 56
W
ei
gh
t[
g]
Days Post TM gavages
* ** ** **
CTRL
Rfx6ΔAdInt
CTRL Rfx6
0
0.5
1
1.5
2
2.5
3
m
m
ol
/l
T. Chol
p=0.06
0
0.5
1
1.5
2
2.5
m
m
ol
/l
HDL Chol
p=0.17
0
0.1
0.2
0.3
0.4
m
m
ol
/l
LDL Chol
***
Triglycerides
0
0.5
1
1.5
2
m
m
ol
/l
p=0.11
0
0.5
1
1.5
m
Eq
/l
FFA
p=0.29
C D E F G
µm
ol
/l
Glycerol
0
100
200
300
400
500 p=0.88
H
0
2
4
6
8
10
12
14
Fo
od
[g
]
Food Intake
***
0
1
2
3
4
5
Fe
ce
s
[g
]
Feces
***
CTRL Rfx6
0
1000
2000
3000
4000
5000
Feces NRJ
content
***
J K L Food efficiency
0
1
2
3
4
***
M
N
0
20
40
60
80
100
120
Li
pa
se
(U
/l)
LipaseI
O
C
on
tro
l
R
fx
6Δ
A
dI
nt
jejunum colon
A B
OGTT IPGTT
C
al
/g
fe
ce
s
er
ne
rg
y
in
ge
st
ed
/e
xc
re
te
d
Figure 3: Energy homeostasis in Rfx6DAdInt mice. (A) Weight follow-up of control and Rfx6DAdInt mice after tamoxifen gavages. n ¼ 9 animals per group (6 males and 3 females)
(B) Oil Red O staining on cryosections from jejunum and colon from Rfx6DAdInt and control animals one month after tamoxifen gavage. (CeE) Blood concentration of total (T. Chol,
C), high density lipoprotein (HDL Chol, D), and low-density lipoprotein cholesterol (LDL Chol, E) in Rfx6DAdInt mice. (FeI) Blood concentration of triglycerides (F), free fatty acids (FFA)
(G), glycerol (H) and lipase (I) in Rfx6DAdInt mice. (JeM) Decreased food efﬁciency and increased food intake and feces production in Rfx6DAdInt mice. Food intake (J) and feces
production (K) of control and mutant mice during 48 h. (L) Energy (NRJ) content of the stools was evaluated in a bomb calorimeter and Food Efﬁciency (M) calculated (calories
ingested/excreted in feces). (CeF) analysis performed 3 months after tamoxifen treatment. (N, O) oral (N, OGTT) and intraperitoneal (O, IPGTT) glucose tolerance tests on adult
control and Rfx6DAdInt mice one month after tamoxifen-induced Rfx6 deletion. n ¼ 5e6 males were analyzed per group. Data are represented as mean  SEM; unpaired t-test,
***p  0.001, **p  0.01*, p  0.05.
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Figure 4: Gene expression proﬁling of the small intestine of adult Rfx6DAdInt mice. (AeF) RNA-Seq analysis of the small intestine (ileum) of adult Rfx6DAdInt mice 8 days (Ae
C) and 3 months (DeF) after Rfx6 deletion. n ¼ 3e4 animals were analyzed per group. (A, D) MA-plot representing the estimated log2 Fold-Change as a function of the mean of
normalized counts. Green and red points represent signiﬁcantly (adjusted p-value  0.05) up- and down-regulated genes, respectively in Rfx6DAdInt versus controls, 8 days (A) or 3
months (D) after Rfx6 deletion (RNA-Seq data). (B, C, E, F) Histograms showing RNA-Seq data for a selection of genes encoding enteroendocrine hormones or the rate limiting
enzyme Tph1 for serotonin synthesis (B, E) or transcription factors (C, F). All controls values are adjusted to 1. ns: non-signiﬁcant, adjusted p-value >0.05 between controls and
mutant. For all other genes adjusted p-value is  0.05. (G, H) RT-qPCR expression analysis of relevant genes in Rfx6DAdint duodenal organoids, 8 days after a 15 h treatment with
1.25 mM tamoxifen (4-OHT) to delete Rfx6 gene. Data are represented as mean  SD. Organoids were generated from n ¼ 4 mice per group. Statistics: non-parametric Manne
Whitney test, *p  0.05, ns, non signiﬁcant.
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5-HT/serotonin-generating enzyme in EC-cells, was up-regulated in
the small and large intestine of Rfx6DAdInt mice. Tph1 transcripts were
increased as early as one week after Rfx6 removal, in the duodenum
(Suppl. Figure 5A) and ileum (Figure 4B), and after one month in the
jejunum and colon of Rfx6DAdInt mice (Suppl. Figure 5B). Accordingly,
ChgA expression, known to be enriched in EC-cells, was increased
likewise upon Rfx6 deletion (Figure 4E, Suppl. Figure 5B). In agreement
with the transcriptomic data, we have not been able to ﬁnd any GLP1-,
GIP-, CCK-, or SST-expressing cell by immunoﬂuorescence while only
few SCT-positive cells were detected (Suppl. Figure 6). To the contrary,
the number of serotonin (5-HT)-positive cells was increased already 1
week after Rfx6 deletion compared to controls (Figure 5D). Conse-
quently, mucosal 5-HT content was higher in Rfx6DAdInt mice
(Figure 5E). These observations suggest that the differentiation of
endocrine cells producing peptides is impaired in the absence of Rfx6,
while the number of 5-HT cells is increased. Apart from the endocrine
lineage, we did not observe any perturbation of the differentiation of
other intestinal epithelial cells - including Paneth cells, goblet-cells or
enterocytes - or of the crypts/villi morphogenesis (Suppl. Figure 4).
To determine the position of Rfx6 in the transcriptional network
controlling enteroendocrine cell differentiation, we next examined
the expression of transcription factors known to control enter-
oendocrine cell differentiation. We found that Arx, Isl1 and Pax6 are
strongly decreased (Figure 4C,F, Suppl. Figure 5A) as early as 1
week after tamoxifen treatment, in agreement with the impaired
differentiation of peptidergic enteroendocrine cells and suggesting
that Rfx6 acts upstream of these transcription factors. In contrast,
the expression of several transcription factors, such as Pax4, was
up-regulated (Figure 4C,F, Suppl. Figure 5); Pax4 is also up-
regulated in Rfx6-deﬁcent pancreatic beta cells. Neurog3 tran-
scripts are increased as well, suggesting that Rfx6 deletion perturbs
endocrine progenitor cells development (Figure 5). Importantly, we
also found that Lmx1a is increased upon Rfx6 deletion in the adult
intestine, and so it is the case for Nkx2-2, an upstream regulator of
Lmx1a, 3 months after tamoxifen treatment. Lmx1a upregulation
likely explains the increased expression of Tph1, the rate limiting
enzyme for serotonin synthesis. RNA-Seq did not reveal any
changes in expression for other endocrine transcription factors,
such as Insm1, Sox4, NeuroD1 or for Atoh1, which is necessary for
secretory lineage speciﬁcation. Unaltered gene expression reﬂects
that the average gene expression levels are unchanged, which does
not exclude variation in single cells, or that gene expression is
independent of Rfx6. Taken together, our results suggest that Rfx6
controls transcriptional programs which promote the differentiation
of enteroendocrine cells expressing peptide hormones (PE cells)
while repressing the differentiation of enterochromafﬁn cells
secreting serotonin (EC cells) in the digestive tract.
We next addressed whether Rfx6 similarly controls enteroendocrine
cell differentiation in Rfx6DAdInt small intestinal organoids
(Figure 4G,H). Brieﬂy, tamoxifen was added to organoids cultures to
remove Rfx6, and organoids were analyzed 8 days after treatment.
As expected, RT-qPCR analysis conﬁrmed the decreased expression
of Gip, Gcg, and Cck (Sct unchanged) upon Rfx6 deletion. Unex-
pectedly, Tph1 expression was also decreased, as were Ucn3 and
Tac1, two other markers of EC cells (see last section results). In
agreement with the decreased expression of EC enriched genes,
Lmx1a was down-regulated as well in this culture system, sug-
gesting that the consequences of Rfx6 removal on EC cells differ-
entiation programs are different in vivo and ex vivo.MOLECULAR METABOLISM 29 (2019) 24e39  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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absorption machinery genes in the small intestine of mice upon Rfx6
deletion
To evaluate the long-term effect of impaired enteroendocrine cell
function and lipid metabolism consecutively to Rfx6 deﬁciency, we
examined the expression of intestinal genes that are not endocrine
speciﬁc. Surprisingly we observed a strong and fast upregulation of
genes involved in intestinal gluconeogenesis [48]. These include
Fructose 1,6 biphosphatase (Fbp1) and Glucose 6 phosphatase (G6pc)
as well as Glutaminase (Gls), the enzyme which hydrolyzes glutamine,
the main gluconeogenic substrate in the small intestine (Figure 4A,D,
Suppl. Table 4). The expression of the gene encoding the brush border
enzyme sucrase-isomaltase (Sis), which hydrolyzes dietary carbohy-
drates was also found to be up-regulated. A major long-term adap-
tation to intestinal Rfx6 deletion that was not observed at 1 week, is the
strong upregulation of the glucose transporter type 2 Slc2a2 (also
known as Glut2). Slc2a2 transporter is thought to facilitate the passage
of dietary sugars in the blood stream [49] at the basolateral side of
enterocytes. The expression of the sodium-coupled co-transporter
Sglt1, which triggers glucose absorption at the apical membrane of
enterocytes, was however not differentially expressed. We also found
an up-regulation of Apoa4, an important chylomicron component, as
well as of other apoliproteins such as Apoc3, Apoc2, and their up-
stream regulator, the transcription factor Creb3l3/CREB-H [50].
Together, our data suggest that Rfx6DAdInt mice adapt to overcome
decreased food efﬁciency by promoting intestinal glucose and lipid
absorption as well as glucose production.
3.7. Increased number of enteroendocrine progenitors in intestinal
crypts of Rfx6DAdInt mice
Unexpectedly, when analyzing RNA-Seq data, we found increased
levels of Neurog3 transcripts in the ileum of adult Rfx6DAdInt mice 3
months after Rfx6 deletion (Figure 4C,F). Similarly, RT-qPCR data
showed that Neurog3 was up-regulated in the jejunum (2-fold) and in
the colon (1.6-fold) compared to controls (Figure 5A) and in the duo-
denum as early as one week after Rfx6 deletion (Suppl. Figure 5A).
Similar results were observed in Rfx6DInt neonates (Suppl. Figure 2).
Morphometric analysis revealed a 1.3e5 fold increase in the number
of Neurog3-cells per mm2 in all segments of the small intestine as well
as in the colon of Rfx6DAdInt mice (Figure 5B). To determine whether
the increased pool of enteroendocrine progenitors resulted from an
increased proliferation of endocrine progenitors, we quantiﬁed the
percentage of Neurog3þ/BrdUþ double-positive cells. Neurog3 cell
proliferation was not affected in the duodenum and jejunum while was
increased in the ileum and colon (Figure 5C). Neurog3-positive cells
did not co-stain for 5-HT (Figure 5F), suggesting that the increased
number of 5-HT-positive cells does not result from premature
expression of 5-HT in enteroendocrine progenitors. Taken together, our
results support that the increase of Neurog3 transcripts in Rfx6-deﬁ-
cient intestine results from increased number of enteroendocrine
progenitors.
3.8. Single cell transcriptomics revealed Rfx6 dependent genetic
programs in the peptidergic enteroendocrine and enterochromafﬁn
cell lineages
To gain knowledge into the mechanisms controlling enteroendocrine
cell differentiation and diversity as well as into the role of Rfx6, we
performed single-cell RNA sequencing of sorted EECs. Enteroendocrine
cells were captured at various stages of their development, fromcess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 33
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Figure 5: Increased number of Neurog3-positive endocrine progenitors and 5-HT-positive cells upon Rfx6 deletion in the adult intestine. (A) RT-qPCR. Expression of
Neurog3 mRNA in the adult jejunum and colon three months after Rfx6 deletion (n ¼ 4 mice per group). Unpaired t-test. (B) Quantiﬁcation of the number of Neurog3-positive cells
per mm2 of tissue in each segment of the adult intestine (n ¼ 3e4 mice per group) three months after Rfx6 deletion. (C) Quantiﬁcation of the number of proliferating Neurog3þ
cells expressed as the percentage of BrdUþ/Neurog3þ cells on total Neurog3þ cells. (D) Quantiﬁcation of the number of 5-HT-positive cells per mm2 of tissue in the duodenum
and ileum of Rfx6DAdInt and control mice, 8 days after Rfx6 deletion (n ¼ 3 mice per group). (E) Mucosal 5-HT content analysis throughout the intestinal tract from day 11 of
tamoxifen-treated control Rfx6DAdInt mice (n ¼ 3e4 mice per group). Biopsies were sampled from Duodenum (Duo), Jejunum (Jej), Ileum, Prox. Colon (P. colon) and Dist. Colon (D.
colon). 5-HT content were analyzed on a HPLC-ECD and results stated as area under the curve (AUC). (F) Double immunoﬂuorescence for Neurog3 and 5-HT on duodenal
cryosections of control and Rfx6DAdInt mice (8 days post Tamoxifen treatment). Red and green arrows in D and E point to some Neurog3-and 5-HT-positive cells, respectively. Data
are represented as mean  SD; unpaired t-test was applied to calculate signiﬁcance *p  0.05; **p  0.01. Scale bar represents 50 mm.
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endocrine progenitors to hormone expressing cells. Endocrine cells
were puriﬁed from Neurog3eYFP/þ mouse intestinal organoids. In this
model, due to the stability of the eYFP protein, both crypt-based
endocrine progenitors as well as differentiating hormone-expressing
EECs express the ﬂuorescent reporter (Figure 6A and
Suppl. Figure 7). After data ﬁltering, 290 cells were analyzed. Shared
Nearest Neighbor (SNN) clustering revealed eight groups of cells
(Figure 6B and Suppl. Figure 8A) which were visualized in two di-
mensions using the Uniform Manifold Approximation and Projection
(UMAP) algorithm. These clusters include 4 groups of progenitors (P1-
4); P2eP4 expressing the endocrine progenitor marker Neurog3 (Figure
6B and Suppl. Figure 8A). Group P1 expressed markers of Paneth (Defa
17, Lyz1) and goblet (Muc2, Tff3) cells, suggesting multiple lineages
priming in secretory progenitors as previously described [51]. The four
other clusters represent subsets of Enterochomafﬁn cells (EC early and
EC) expressing Tph1 (Figure 6E and Suppl. Figure 8A), and Peptidergic
Enteroendocrine cells (PE early and PE) expressing Glc, Cck, Sct, Gip,
Ghrl, and Sst (Figure 6F and Suppl. Figure 8A), at different stages of
maturation. Clusters gene signatures included known and novel makers
of EC and PE cells. Single-cell analysis conﬁrmed that Rfx6 is expressed
both in endocrine progenitors as well as in more mature enter-
oendocrine cells of both EC and PE lineages (Figure 6D,O) and that
single EECs can co-express several hormones genes (Figure 6O).
Temporal resolution of transcriptome dynamics using diffusion map
algorithm predicted cell state transition trajectories. Data analysis
showed that endocrine progenitors differentiate in two branches: the EC
and PE lineages (Figure 6C). Examples of genes expressed along the EC
and PE branches are shown in Figure 6GeN and Suppl. Figure 9.
Importantly, pseudotemporal ordering of single cells also revealed dy-
namics of transcription factors during EC or PE cell differentiation
(Figure 6 and Suppl. Figure 9). Some transcription factors were clearly
enriched in EC (Lmx1a, Mnx1, Atf6, Glis3, Lhx1) or PE (Arx, Isl1, Pax6,
Etv1) lineage branches. Some other transcription factors (Pax4, Neu-
rod1, Nkx2-2, Insm1, Mlxipl), like Rfx6, were found both in progenitors
and more mature enteroendocrine cells (Suppl. Figure 9 Q-X) but were
not speciﬁcally enriched in EC and PE lineages according to our se-
lection criteria.
Our data show that Rfx6 differentially controls genetic programs
regulating PE and EC cells, which appeared to be the two main EEC
lineages. We thus determined, among the genes deﬁning the signature
of PE and EC lineages, which ones were actually regulated by Rfx6 in
the adult small intestine (Figure 6P and Suppl. Figure 8B). As expected,
most PE enriched genes, like hormone genes (e.g., Sct, Gcg, Gip, Sst,
Cck), related transcription factors (e.g. Arx, Isl1, Pax6), GPCRs (e.g
Gpr119, Ffar1), as well as other PE markers (Abcc8, Scgn, Fapb5)
were down regulated in absence of Rfx6. Surprisingly rare PE enriched
genes were either up-regulated (Rbp2) or have their expression un-
changed (Gpr112, Rbp4, Scg3, data not shown). Furthermore, the vast
majority of EC enriched genes were up-regulated in absence of Rfx6,
including endocrine markers (Tph1, ChgA, Scn3a), transcription factors
(Lmx1a, Glis3), GPCRs (Olfr558, Olfr78) or other markers (e.g Cacna1d,
Disp2, Cwh43). However, the expression of highly speciﬁc markers of
the EC lineage was not affected (e.g Tac1, Ucn3, Lhx1, Mnx1, Atf6) or
decreased (Pappa2, Ly6a) by the loss of Rfx6. Taken together, these
results suggest that Rfx6 regulates speciﬁc genetic programs in the EC
and PE lineages, while others genes are independent of Rfx6.
4. DISCUSSION
Mutations in RFX6 cause MitchelleRiley syndrome in humans. This
syndrome is characterized by neonatal diabetes and intestinal failuresMOLECULAR METABOLISM 29 (2019) 24e39  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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controls beta-cell development in the mouse embryo as well as insulin
secretion in adult mouse and human beta cells [22,23,32]. However,
the function of Rfx6 in the mouse intestine was unknown. In this study,
we show that, as in the pancreas, Rfx6 is expressed in Neurog3-
endocrine progenitors and persists in all hormone-expressing cells
in the intestine, not only in Gip-expressing cells as previously thought
[25]. In all cases, constitutive or inducible intestinal deletion of Rfx6 in
mice resulted in a severe loss of enteroendocrine cells expressing
peptide hormones while enterochromafﬁn cells were still present and
genes controlling serotonin-production were increased. Unlike new-
borns that die, adult mice can cope with the induction of this massive
reduction of peptidergic EECs. However, intestinal absorption is per-
turbed, leading to impaired food efﬁciency. RNA-Seq revealed
enhanced expression of neoglucogenic and nutrient absorption ma-
chinery genes that we hypothesize to be a compensatory mechanism
to cope with the malabsorption. Importantly, using single-cell tran-
scriptomics, we found that EECs differentiate from endocrine pro-
genitors according to two cell differentiation trajectories: the
Enterochromafﬁn cells (EC) and Peptidergic Enteroendocrine (PE) cells.
Similar conclusions were drawn recently in a single-cell proﬁling of
EECs [5]. Identiﬁcation of speciﬁc gene signatures and dynamics in the
EC and PE lineages allowed us to determine their respective depen-
dence on Rfx6. We propose that Rfx6 positively regulates genetics
programs leading to PE cells differentiation, and represses 5-HT pro-
duction, as well as other, but not all, EC cell speciﬁc programs
(Figure 7).
In addition to the severe alteration in Peptidergic Enteroendocrine cell
differentiation, our studies demonstrated that constitutive inactivation
of Rfx6 leads to gastric heterotopia in the embryonic mouse intestine.
Heterotopic gastric mucosa was reported in only 3 patients carrying
compound heterozygote mutations in RFX6 [30,31]. These patches of
gastric heterotopia were revealed after histological analysis of intes-
tinal resection to treat hemorrhagic ulcers. It has been proposed that
mucosa alteration could be caused by acid secretion of the ectopic
gastric tissue [31]. It is likely that gastric heterotopia is a general
feature of patients with RFX6 mutations, since anemia and melena
were reported in many cases and could result from intestinal bleeding
[31]. Importantly, we observed gastric tissue only in the intestine of
mice with a constitutive deletion of Rfx6 and never when Rfx6 was
deleted in the endocrine lineage or when Rfx6 was inactivated in the
adult intestine. These observations suggest that gastric heterotopia is
unrelated to the impairment of the endocrine lineage but rather results
from an early function of Rfx6 in mouse endoderm patterning, similarly
to what has been suggested in Xenopus [24]. Nevertheless, we did not
observe any gross defect of intestinal or gastric organogenesis, sug-
gesting functional redundancy. The patchy pattern of gastric tissue in
Rfx6-deﬁcient intestine might thus be explained by the lack of func-
tional compensation in some pluripotent endodermal stem cells that
consequently lost or did not acquire the proper regional identity. In one
case, ectopic pancreatic tissue was also reported in the jejunum [31], a
feature that we did not observe in Rfx6-deﬁcient mice. Of note, it has
been suggested that in the human gut the loss of Foxo1 expression,
particularly in EC cells, results in ectopic insulin expression [52]. We
did not observe any changes in FOXO1 expression in Rfx6DAdInt in-
testine and did not detect any expression of Ins1 or Ins2 in the em-
bryonic or adult intestine lacking Rfx6, suggesting that expanded EC
cells do not express insulin.
Rfx6 inactivation led to an increased expression of Tph1, which is
critical for 5-HT biosynthesis in enterochromafﬁn cells, at all stages
and conditions studied in vivo throughout the intestine. Furthermore,cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 35
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Figure 6: Single-cell RNA-Seq analysis of enteroendocrine cells of adult small intestine and Rfx6-dependent genetic programs. (A) Small intestinal organoid of Neu-
rog3eYFP/þ mice (intrinsic eYFP ﬂuorescence). eYFP labels Neurog3-positive endocrine progenitors and differentiated enteroendocrine cells. After organoid cell dissociation,
ﬂuorescence activated cell sorting (FACS) is used to isolate individual endocrine cells in 96 well plates. scRNA-Seq is then used to proﬁle the cells. (B) Uniform Manifold
Approximation and Projection (UMAP) representing the cell clusters. The 290 single cells were clustered based on the expression of 830 biologically variable genes. EC:
Enterochromafﬁn cells; EC early: precursors of EC cells; PE: Peptidergic Enteroendocrine cells; PE early: precursors of PE cells; P1-4:groups of progenitors. (C) Cell clusters along
the cell trajectory. Diffusion map, built from the log-expression of 830 biologically variables genes, was used to reconstruct the cell trajectory. (DeF) UMAP representing the
expression of Rfx6, Tph1 and Gip (normalized counts) in the 290 single cells. (GeN) Expression (normalized counts) of genes enriched in the EC (GeJ) and PE (KeN) branches
along the cell trajectory. (O) Heatmap (normalized counts) showing expression of hormone genes and Rfx6 in individual cells. (P) Heatmap (Z-score of normalized counts) showing
expression of some markers of EC and PE lineages affected by Rfx6 deletion, in Rfx6DAdInt (3 months after Rfx6 removal) and control conditions. Shown is the expression (row-wise
Z-score), in Rfx6DAdInt and control conditions, of markers of EC populations (EC and/or EC-early populations) and PE populations (PE and/or PE-early populations) which are
differentially expressed after Rfx6 deletion.
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Figure 7: Proposed model for the role of Rfx6 in enteroendocrine lineages
speciﬁcation in the adult intestine. Neurog3 triggers the endocrine fate. Rfx6 is then
activated in endocrine progenitors downstream of Neurog3 and represses Neurog3
transcription allowing differentiation to proceed. Rfx6 promotes peptidergic endocrine
(PE) cell differentiation upstream of Arx, Isl1 and Pax6. Rfx6 represses, upstream of
Lmx1a, a genetic program leading to Tph1 expression and 5-HT production. Green and
Red: genes respectively down or up-regulated in the Rfx6DAdInt compared to wild-type
controls.we measured an increased number of 5-HT-positive cells and mucosal
5-HT content in the adult small intestine upon Rfx6 removal. We thus
propose that Rfx6 represses 5-HT biosynthesis. Of note, we found that
the expression of Lmx1a, which is downstream of Nkx2-2 and has
been shown to control the expression of Tph1 [53], was up-regulated.
This suggests that increased Tph1 results from increased Lmx1a. By
contrast, Nkx2-2 transcripts were unaffected one week after Rfx6
deletion, suggesting that Rfx6 does thus not repress Lmx1a via Nkx2-
2. However, 3 months after the tamoxifen treatment, Nkx2-2
expression was increased; therefore, we cannot exclude a contribution
of Nkx2-2 in Lmx1a and Tph1 up-regulation at a later stage. Impor-
tantly, the unchanged expression of several speciﬁc markers of the EC
lineage, identiﬁed in our single cell transcriptome study of enter-
oendocrine cells, such as Ucn3, Tac1, Atf6, Lmx1a, and Mnx1, sug-
gests that Rfx6 does not act as a genetic switch promoting PE and
inhibiting EC destiny. Rather, Rfx6 represses the genetic program
leading to 5-HT biosynthesis and possibly others speciﬁc features of
EC cells. However, as some of these genes are also expressed outside
of enterochromafﬁn cells, such as Ucn3 and Tac1, which are found in
enteric neurons [54], it is possible that we could not detect variation in
their mucosal expression when performing bulk RNA-Seq on the entire
intestinal tissue. Of note, the cellular origin of the increased expression
of Lmx1a and Tph1 remains unclear. One hypothesis is that the loss of
Rfx6 results into the ectopic induction of the serotonergic program in
the PE lineage. Another possibility would be that Rfx6 modulates the
levels of 5-HT in EC cells by controlling the expression of Lmx1a and
Tph1. The absence of cells co-expressing Neurog3 and 5-HT in
Rfx6DAdInt mice suggests that Rfx6 does not represses the serotonergic
program in enteroendocrine progenitors but rather at later stages of
EECs differentiation.
Our study also sheds light on the position of Rfx6 in the regulatory
network of transcription factors controlling EECs differentiation. We
found that Pax6, Isl1, and Arx are down-regulated, while Pax4 is up-
regulated by the inactivation of Rfx6 suggesting that Rfx6 operates
upstream of these transcription factors. In Arx-deﬁcient mice, the
expression of Gcg, Gip, Cck, and Nts was reduced [15,16], suggesting
that Rfx6 regulates the expression of these hormone-encoding genes
through the regulation of Arx. Pax4 and Arx are known to repress each
other in the developing pancreas [55]. However, this does not seem to
be the case in the gut. Indeed, Pax4 expression is unchanged in Arx-
deﬁcient intestine [15]. Thus, in the absence of Rfx6, increased Pax4
expression is probably not a consequence of Arx down-regulation.
Nevertheless, Pax4 was shown to be required for EC cell differentia-
tion [15], in agreement with the maintenance of EC cells in Rfx6-MOLECULAR METABOLISM 29 (2019) 24e39  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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resulted in the loss of GLP-1, GIP, CCK, and SST expressing cells and
an increase in 5-HT producing cells [18]. It is thus likely that Isl1
contributes to the regulation of PE cells differentiation, downstream of
Rfx6 and also to the repression of 5-HT production through a mech-
anism that remains to be elucidated. We previously reported that
constitutive intestinal inactivation of Neurog3 (using Villin-Cre) led to a
total loss of EECs, including 5-HT expressing cells [12]. Despite this,
50% of the Neurog3DInt mice, which display a more severe enter-
oendocrine phenotype than Rfx6DInt mice, survived to adulthood,
probably because they were kept on a more robust CD1 genetic
background. Thus, Rfx6 is turned on in endocrine progenitors and
operates downstream of Neurog3 to regulate a network of transcription
factors including Lmx1a, Pax4, Arx, Pax6, and Isl1 which will control
later steps of EEC differentiation. Our study revealed that Neurog3
expression and the number of Neurog3-positive endocrine progenitor
cells increased upon induction of Rfx6 deletion in both the small in-
testine and colon. One explanation for this increase would be that Rfx6
normally represses Neurog3 expression in late endocrine progenitors.
Alternatively, endocrine progenitors accumulate because they cannot
differentiate further into peptidergic enteroendocrine cells. Interest-
ingly, we found that Arx, Pax4, Pax6, Isl1, and Neurog3 are similarly
regulated by Rfx6 in the adult gut and in the embryonic pancreas [23,
and our unpublished data)] further conﬁrming the conservation of gene
regulatory pathways during the differentiation of enteroendocrine and
islet cells. Of note, the use of Rfx6ﬂ/ﬂ mice as controls is a possible
limitation of our study, given that impaired intestinal regeneration as
recently been reported in Villin-CreERT2 mice [56]. Nevertheless, we
believe that the lack of Rfx6 is solely causative of the enteroendocrine
failure in adult mice since a very similar phenotype was observed in
Rfx6/ newborn mice which lack any CreERT2 transgene.
Unexpectedly, when we studied the consequences of the induction of
Rfx6 deletion in small intestine organoid cultures, we found that the
development of all EECs was impaired, including EC cells. In line with
this observation, the expression of Lmx1a and Tph1 were down-
regulated ex vivo upon Rfx6 deletion. A similar conclusion was re-
ported recently in a study in which Rfx6 was inactivated directly,
ex vivo, in mouse intestinal organoids [5]. We propose that these
in vivo/ex vivo differences on the role of Rfx6 in EC cell development
could reﬂect limitations of the organoid culture system to faithfully
mimic alternative cell differentiation pathways when genetic networks
are perturbed. We cannot exclude that the promotion of serotonergic
programs in the absence of Rfx6 results from an adaptation due to a
systemic effect or an effect of the microbiota that would not occur
ex vivo. However, we do not favor this hypothesis as we saw the in-
duction of Lmx1a and/or Tph1 when Rfx6 is lacking, not only in the
adult but also in the embryonic intestine and in the developing stomach
suggesting a general function of Rfx6 in repressing enterochromafﬁn
cell differentiation. Nevertheless, these ﬁndings highlight the necessity
of generating more sophisticated intestinal organoid models in the
future, models which are innervated, vascularized, and contain a
microbiome, smooth muscle or immune cells since all can eventually
impact intestinal epithelial cell differentiation.
In conclusion, this study revealed that Rfx6 is essential, downstream of
Neurog3, for the differentiation of peptidergic enteroendocrine cells
during development and in the adult. Rfx6-dependent impairment of
enteroendocrine cells perturbs food efﬁciency. In addition, we show
that Rfx6 also represses genetic programs leading to the biosynthesis
of 5-HT. These ﬁndings shed new light on the molecular mechanisms
underlying intestinal malabsorption and energy metabolism in RFX6
deﬁciency in humans.cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 37
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